Lunai Bioworks Introduces Fresh Corporate Branding
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 30 2025
0mins
Should l Buy ?
Corporate Rebranding: Lunai Bioworks has officially adopted its new identity, transitioning from Renovaro Inc. to reflect a focused strategy and streamlined capital structure after a 10:1 reverse stock split.
Strategic Mission: The rebranding emphasizes Lunai's commitment to leveraging AI for biological signal decoding and validation, positioning the company as a leader in therapeutic innovation and biodefense, with its stock set to trade under the new ticker "LNAI" on Nasdaq starting September 30, 2025.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
